Dana-Farber Cancer Institute | Strategic Alliance Partners

Dr Mittendorf discusses her priorities for advancing patient care and supporting up-and-coming oncology professionals during her 2026-2027 ASCO presidency.

Sarah Sammons, MD, discusses early efficacy data with RLY-2608 plus fulvestrant in PIK3CA-mutant, hormone receptor–positive, HER2-negative breast cancer.

Trastuzumab deruxtecan plus pertuzumab produced a statistically significant PFS improvement in frontline HER2-positive advanced breast cancer.

Zilovertamab vedotin plus R-GemOx elicits responses in patients with relapsed or refractory diffuse large B-cell lymphoma.

Frontline sacituzumab govitecan plus pembrolizumab improved PFS vs chemotherapy plus pembrolizumab in PD-L1+ metastatic triple-negative breast cancer.

Paul G. Richardson, MD, discusses the activity of quadruplet regimens containing daratumumab or isatuximab in patients with 1q-amplified multiple myeloma.

Here is your snapshot of all therapeutic options that were approved by the FDA in May 2025 spanning tumor types.

Paolo Tarantino, MD, PhD, discusses the need for prospective clinical trials to identify treatments for HER2+ breast cancer following progression on T-DXd.

Dana-Farber researchers unveil insights into aggressive pediatric brain tumors, paving the way for targeted therapies and improved patient outcomes.

The top 5 OncLive videos of the week cover insights in HER2+ breast cancer, myeloma, pancreatic cancer, prostate cancer, and sarcoma.

Yufei Wang, PhD, discusses how the metastasis of ccRCC could rewire the tumor microenvironment and lead to increased immunosuppression and fibrosis.

Elena Maroto-Martin, PhD, discusses early efficacy data with an MZB1-targeted TCR-like CAR T-cell therapy in multiple myeloma and Waldenström macroglobulinemia.

Paolo Tarantino, MD, PhD, discusses potentially practice-changing breast cancer research that will be presented at the 2025 ASCO Annual Meeting.

Elena Maroto-Martin, PhD, discusses the rationale for developing TCR-like CAR T-cell therapy in multiple myeloma and other hematologic malignancies.

Paolo Tarantino, MD, discusses the clinical implications of current risk stratification methods for patients with HER2-positive breast cancer.

Dana-Farber Cancer Institute opened the Ning Zhao & Ge Li Simulation Center, which is devoted exclusively to ambulatory oncology care.

Elizabeth Lee, MD, discusses the need for FRα-targeted therapies with differing payloads for patients with platinum-resistant ovarian cancer.

Erica Maria Pimenta, MD, PhD, discusses a study investigating potential defects in molecular pathways involved in adipocyte-specific differentiation

Glenn J. Hanna, MD, discusses the efficacy of elraglusib plus chemotherapy with or without immunotherapy in patients with advanced salivary gland cancer.

Penpulimab gets green light from FDA for nasopharyngeal carcinoma, sacituzumab govitecan combination boosts PFS in TNBC, and more.

Experts from across oncology specialties highlight research being presented at the 2025 AACR Annual Meeting.

Jennifer Chan, MD, MPH, highlights the significance of the FDA approval of cabozantinib for the treatment of patients with pNET and epNET.

Investigators found that the cancer-controlling effects of immune checkpoint inhibitors continue even after treatment is stopped due to immune-related adverse events in patients with advanced NSCLC.

Sara M. Tolaney, MD, MPH, discusses the value of incorporating ctDNA monitoring of ESR1 mutations into routine management for HR-positive breast cancer.

The top 5 OncLive videos of the week cover insights in multiple myeloma, AL amyloidosis, myelofibrosis, breast cancer, and sarcoma.

Sara M. Tolaney, MD, MPH, discusses the ideal time for patients with HR-positive breast cancer to undergo genetic testing for ESR1 mutations.

Paolo Tarantino, MD, discusses the growing emphasis on anthracycline-sparing approaches for the treatment of HER2-positive breast cancer.

Three researchers from Dana-Farber Cancer Institute have been selected by the American Association for Cancer Research (AACR) as recipients of 2025 Scientific Achievement Awards.

K. “Vish” Viswanath, PhD, of Dana-Farber Cancer Center, has been named Fellow of the American Association for the Advancement of Science.

Panagiotis A. Konstantinopoulos, MD, PhD, discusses CRs achieved with letrozole, abemaciclib, and metformin in ER–positive endometriod endometrial cancer.